nach oben

Current Treatment Options in Gastroenterology

Erschienen in:

17.03.2022 | Liver (J Bajaj, Section Editor)

Symptom Management in Patients with Cirrhosis: a Practical Guide

verfasst von: Alyson Kaplan, Russell Rosenblatt

Erschienen in: Current Treatment Options in Gastroenterology | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose of the review

Though it is well known that cirrhosis is associated with significant morbidity and mortality, management of symptoms in cirrhosis can be difficult. This review serves to offer practical guidance in the management of liver-specific symptoms of cirrhosis as well as other symptoms with special hepatic considerations.

Recent findings

We discuss liver-specific symptoms and management, including ascites and refractory ascites, hepatic encephalopathy, pruritus, and muscle cramping. We also discuss the challenges of treating more generalized symptoms in cirrhosis, including pain, depression/anxiety, appetite, and fatigue. Medication management is, especially complex in this population given the altered metabolism of drugs, and we consider some strategies to approach this.

Summary

With the right tools, provided throughout this review, hepatologists should be well equipped to manage the nuanced liver-specific and generalized symptoms in patients with cirrhosis.

Centers for Disease Control and Prevention. CDC Wonder.

Younossi ZM, Boparai N, Price LL, Kiwi ML, McCormick M, Guyatt G. Health-related quality of life in chronic liver disease: the impact of type and severity of disease. Am J Gastroenterol. 2001;96:199–205. https://doi.org/10.1111/j.1572-0241.2001.03956.x.CrossRef

3•.

Waterman BL, Ramsey SU, Whitsett MP, et al. Top ten tips palliative care clinicians should know about end-stage liver disease. J Palliat Med. 2021;24(6):924–31. https://doi.org/10.1089/jpm.2021.0097. Very helpful recently published tips about palliative care's role in end-stage liver disease. It has a very detailed table of commonly used medications and their potential risks when used in patients with liver disease.CrossRefPubMed

Planas R, Montoliu S, Ballesté B, et al. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol. 2006;4:1385–94. https://doi.org/10.1016/j.cgh.2006.08.007.CrossRefPubMed

Hansen L, Chang MF, Lee CS, et al. Physical and mental quality of life in patients with end-stage liver disease and their informal caregivers. Clin Gastroenterol Hepatol. 2021;19(1):155–61. https://doi.org/10.1016/j.cgh.2020.04.014.CrossRefPubMed

6•.

Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the study of liver diseases. Hepatology. 2021;74(2):1014–48. https://doi.org/10.1002/hep.31884. The most recent AASLD guidelines regarding management.CrossRefPubMed

Morando F, Rosi S, Gola E, et al. Adherence to a moderate sodium restriction diet in outpatients with cirrhosis and ascites: a real-life cross-sectional study. Liver Int. 2015;35(5):1508–15. https://doi.org/10.1111/liv.12583.CrossRefPubMed

De Gottardi A, Thévenot T, Spahr L, et al. Risk of complications after abdominal paracentesis in cirrhotic patients: a prospective study. Clin Gastroenterol Hepatol. 2009;7:906–9. https://doi.org/10.1016/j.cgh.2009.05.004.CrossRefPubMed

De Gottardi A, Thévenot T, Spahr L, et al. Risk of Complications after abdominal paracentesis in cirrhotic patients: a prospective study. Clin Gastroenterol Hepatol. 2009;7(8):906–9. https://doi.org/10.1016/J.CGH.2009.05.004.CrossRefPubMed

10.

Parker R. Role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension. Clin Liver Dis. 2014;18(2):319–34. https://doi.org/10.1016/J.CLD.2013.12.004.CrossRefPubMed

11•.

Bureau C, Thabut D, Oberti F, et al. Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites. Gastroenterology. 2017;152:157–63. https://doi.org/10.1053/j.gastro.2016.09.016. Very helpful recently published tips about palliative care's role in end-stage liver disease. It has a very detailed table of commonly used medications and their potential risks when used in patients with liver disease.CrossRefPubMed

12.

Yin X, Zhang F, Guo H, et al. A nomogram to predict the risk of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in cirrhotic patients. Sci Rep. 2020;10(1):1–8. https://doi.org/10.1038/s41598-020-65227-2. CrossRef

13.

Forauer AR, McLean GK. Transjugular intrahepatic portosystemic shunt constraining stent for the treatment of refractory postprocedural encephalopathy: a simple design utilizing a Palmaz stent and Wallstent. J Vasc Interv Radiol. 1998;9(3):443–6. https://doi.org/10.1016/S1051-0443(98)70296-9.CrossRefPubMed

14.

Bai M, Qi X, Yang Z, et al. Predictors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in cirrhotic patients: a systematic review. J Gastroenterol Hepatol. 2011;26(6):943–51. https://doi.org/10.1111/J.1440-1746.2011.06663.X.CrossRefPubMed

15.

Nardelli S, Lattanzi B, Torrisi S, et al. Sarcopenia is risk factor for development of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt placement. Clin Gastroenterol Hepatol. 2017;15(6):934–6. https://doi.org/10.1016/J.CGH.2016.10.028.CrossRefPubMed

16.

LaFond JP, Shah NL. Bursting with symptoms: a review of palliation of ascites in cirrhosis. Clin Liver Dis. 2016;8(1):10–2. https://doi.org/10.1002/CLD.559.CrossRef

17.

Macken L, Bremner S, Gage H, et al. Randomised clinical trial: palliative long-term abdominal drains vs large-volume paracentesis in refractory ascites due to cirrhosis. Aliment Pharmacol Ther. 2020;52(1):107–22. https://doi.org/10.1111/apt.15802.CrossRefPubMed

18.

Macken L, Hashim A, Mason L, Verma S. Permanent indwelling peritoneal catheters for palliation of refractory ascites in end-stage liver disease: a systematic review. Liver Int. 2019;39(9):1594–607. https://doi.org/10.1111/liv.14162.CrossRefPubMed

19.

Cooper M, Pollard A, Pandey A, et al. Palliative long-term abdominal drains versus large volume paracentesis in refractory ascites due to cirrhosis (REDUCe Study): qualitative outcomes. J Pain Symptom Manage. 2021;62(2):312–25. https://doi.org/10.1016/j.jpainsymman.2020.12.007.CrossRefPubMed

20.

Morando F, Maresio G, Piano S, et al. How to improve care in outpatients with cirrhosis and ascites: A new model of care coordination by consultant hepatologists. J Hepatol. 2013;59(2):257–64. https://doi.org/10.1016/j.jhep.2013.03.010.CrossRefPubMed

21.

Bloom PP, Ventoso M, Tapper E, Ha J, Richter JM. A Telemonitoring intervention for cirrhotic ascites management is cost-saving. Dig Dis Sci. 2021;1:1. https://doi.org/10.1007/S10620-021-07013-2.CrossRef

22.

Gluud LL, Vilstrup H, Morgan MY. Nonabsorbable disaccharides for hepatic encephalopathy: a systematic review and meta-analysis. Hepatology. 2016;64(3):908–22. https://doi.org/10.1002/hep.28598.CrossRefPubMed

23•.

Duong N, Reuter B, Saraireh H, et al. Bowel movement frequency is not linked with cognitive function in cirrhosis. Clin Gastroenterol Hepatol. 2021. https://doi.org/10.1016/J.CGH.2021.05.014. Interesting recently published piece that challenges the practice of basing hepatic encephlopathy treatment dosing on number of bowel movements.CrossRefPubMed

24.

Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362(12):1071–81. https://doi.org/10.1056/nejmoa0907893.CrossRefPubMed

25.

Rifaximin. GoodRx.

26•.

Jesudian AB, Ahmad M, Bozkaya D, Migliaccio-Walle K. Cost-effectiveness of rifaximin treatment in patients with hepatic encephalopathy. J Manag care Spec Pharm. 2020;26(6):750–7. https://doi.org/10.18553/JMCP.2020.26.6.750. Important study that highlights that Rifaximin is cost-effective. This probably argues that it should be made more accessible to patients than it is currently.CrossRefPubMed

27.

Katayama K, Katayama K, Kawaguchi T, et al. The prevalence and implication of zinc deficiency in patients with chronic liver disease. J Clin Med Res. 2018;10(5):437–44. https://doi.org/10.14740/jocmr.v10i5.3374.CrossRefPubMedPubMedCentral

28.

Shen YC, Chang YH, Fang CJ, Lin YS. Zinc supplementation in patients with cirrhosis and hepatic encephalopathy: a systematic review and meta-analysis. Nutr J. 2019;18(1):1–9. https://doi.org/10.1186/S12937-019-0461-3/TABLES/2.CrossRef

29.

Merli M, Berzigotti A, Zelber-Sagi S, et al. EASL Clinical Practice Guidelines on nutrition in chronic liver disease. J Hepatol. 2019;70(1):172–93. https://doi.org/10.1016/J.JHEP.2018.06.024.CrossRef

30.

Plank LD, Gane EJ, Peng S, et al. Nocturnal nutritional supplementation improves total body protein status of patients with liver cirrhosis: a randomized 12-month trial. Hepatology. 2008;48(2):557–66. https://doi.org/10.1002/HEP.22367.CrossRefPubMed

31.

Córdoba J, López-Hellín J, Planas M, et al. Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. J Hepatol. 2004;41(1):38–43. https://doi.org/10.1016/J.JHEP.2004.03.023.CrossRefPubMed

32.

Maharshi S, Sharma BC, Sachdeva S, Srivastava S, Sharma P. Efficacy of nutritional therapy for patients with cirrhosis and minimal hepatic encephalopathy in a randomized trial. Clin Gastroenterol Hepatol. 2016;14(3):454-460.e3. https://doi.org/10.1016/J.CGH.2015.09.028.CrossRefPubMed

33.

Jones EA, Bergasa N. Evolving concepts of the pathogenesis and treatment of the pruritus of cholestasis. Can J Gastroenterol. 2000;14(1):33–9. https://doi.org/10.1155/2000/747495.CrossRefPubMed

34.

Kremer AE, Martens JJWW, Kulik W, et al. Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroenterology. 2010;139(3):1008–18. https://doi.org/10.1053/J.GASTRO.2010.05.009. CrossRefPubMed

35.

Xander C, Meerpohl JJ, Galandi D, et al. Pharmacological interventions for pruritus in adult palliative care patients. Cochrane Database Syst Rev. 2013;9(6):CD008320. https://doi.org/10.1002/14651858.CD008320.pub2.CrossRef

36.

Kumada H, Miyakawa H, Muramatsu T, et al. Efficacy of nalfurafine hydrochloride in patients with chronic liver disease with refractory pruritus: a randomized, double-blind trial. Hepatol Res. 2017;47(10):972–82. https://doi.org/10.1111/HEPR.12830.CrossRefPubMed

37.

Moller P, Bergstrom J, Furst P, Hellstrom K. Muscle biopsy studies in patients with moderate liver cirrhosis with special reference to energy-rich phosphagens and electrolytes. Scand J Gastroenterol. 1984;19:267–72. https://doi.org/10.1080/00365521.1984.12005719.CrossRefPubMed

38.

Takeuchi M, Low PA. Dynamic peripheral nerve metabolic and vascular responses to exsanguination. Am J Physiol - Endocrinol Metab. 1987;253(4):349–53. https://doi.org/10.1152/ajpendo.1987.253.4.e349.CrossRef

39.

Angeli P, Albino G, Carraro P, et al. Cirrhosis and muscle cramps: evidence of a causal relationship. Hepatology. 1996;23(2):264–73. https://doi.org/10.1002/hep.510230211.CrossRefPubMed

40.

Henry ZH, Northup PG. Baclofen for the treatment of muscle cramps in patients with cirrhosis: a new alternative. Hepatology. 2016;64(2):695–6. https://doi.org/10.1002/hep.27988.CrossRefPubMed

41.

Vidot H, Cvejic E, Carey S, et al. Randomised clinical trial: oral taurine supplementation versus placebo reduces muscle cramps in patients with chronic liver disease. Aliment Pharmacol Ther. 2018;48(7):704–12. https://doi.org/10.1111/apt.14950.CrossRefPubMed

42.

Lee FY, Lee SD, Te TY, et al. A randomized controlled trial of quinidine in the treatment of cirrhotic patients with muscle cramps. J Hepatol. 1991;12:236–40. https://doi.org/10.1016/0168-8278(91)90944-7.CrossRefPubMed

43.

Chatrath H, Liangpunsakul S, Ghabril M, Otte J, Chalasani N, Vuppalanchi R. Prevalence and morbidity associated with muscle cramps in patients with cirrhosis. Am J Med. 2012;125(10):1019. https://doi.org/10.1016/J.AMJMED.2012.03.012.CrossRefPubMedPubMedCentral

44.

Chandok N, Watt KDS. Pain management in the cirrhotic patient: the clinical challenge. Mayo Clin Proc. 2010;85:451–8. https://doi.org/10.4065/mcp.2009.0534.CrossRefPubMedPubMedCentral

45.

Wilcock A, Charlesworth S, Prentice W, et al. Prescribing in chronic severe hepatic impairment. J Pain Symptom Manage. 2019;58:515–37. https://doi.org/10.1016/j.jpainsymman.2019.04.034.CrossRefPubMed

46.

Rakoski M, Goyal P, Spencer-Safier M, Weissman J, Mohr G, Volk M. Pain management in patients with cirrhosis. Clin Liver Dis. 2018;11(6):135. https://doi.org/10.1002/cld.711.CrossRef

47•.

Lewis JH, Stine JG. Review article: prescribing medications in patients with cirrhosis - a practical guide. Aliment Pharmacol Ther. 2013;37(12):1132–56. https://doi.org/10.1111/APT.12324. Though slightly older, this is a good review of the safety of various medications in cirrhosis.CrossRefPubMed

48.

Moon AM, Jiang Y, Rogal SS, Tapper EB, Lieber SR, Barritt AS. Opioid prescriptions are associated with hepatic encephalopathy in a national cohort of patients with compensated cirrhosis. Aliment Pharmacol Ther. 2020;51:652–60. https://doi.org/10.1111/apt.15639.CrossRefPubMedPubMedCentral

49.

Tapper EB, Henderson JB, Parikh ND, Ioannou GN, Lok AS. Incidence of and risk factors for hepatic encephalopathy in a population-based cohort of Americans with cirrhosis. Hepatol Commun. 2019;3:1510–9. https://doi.org/10.1002/hep4.1425.CrossRefPubMedPubMedCentral

50.

Randall HB, Alhamad T, Schnitzler MA, et al. Survival implications of opioid use before and after liver transplantation. Liver Transplant. 2017;23:305–14. https://doi.org/10.1002/lt.24714.CrossRef

51.

Mullish BH, Kabir MS, Thursz MR, Dhar A. Review article: depression and the use of antidepressants in patients with chronic liver disease or liver transplantation. Aliment Pharmacol Ther. 2014;40(8):880–92. https://doi.org/10.1111/APT.12925.CrossRefPubMed

52.

Surman OS, Cosimi AB, Dimartini A. Psychiatric care of patients undergoing organ transplantation. Transplantation. 2009;87(12):1753–61. https://doi.org/10.1097/TP.0B013E3181A754D4.CrossRefPubMed

53.

Schlatter C, Egger SS, Tchambaz L, Krhenbhl S. Pharmacokinetic changes of psychotropic drugs in patients with liver disease: implications for dose adaptation. Drug Saf. 2009;32(7):561–78. https://doi.org/10.2165/00002018-200932070-00003.CrossRefPubMed

54.

Fialla AD, Israelsen M, Hamberg O, Krag A, Gluud LL. Nutritional therapy in cirrhosis or alcoholic hepatitis: a systematic review and meta-analysis. Liver Int. 2015;35(9):2072–8. https://doi.org/10.1111/LIV.12798.CrossRefPubMed

55.

Muto Y, Sato S, Watanabe A, et al. Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin Gastroenterol Hepatol. 2005;3(7):705–13. https://doi.org/10.1016/S1542-3565(05)00017-0.CrossRefPubMed

56.

Marchesini G, Bianchi G, Merli M, et al. Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. Gastroenterology. 2003;124(7):1792–801. https://doi.org/10.1016/S0016-5085(03)00323-8.CrossRefPubMed

57.

Gluud LL, Dam G, Les I, et al. Branched-chain amino acids for people with hepatic encephalopathy. Cochrane database Syst Rev. 2017;5(5):CD001939. https://doi.org/10.1002/14651858.CD001939.PUB4.CrossRefPubMed

58.

Palmer LB, Kuftinec G, Pearlman M, Green CH. Nutrition in Cirrhosis. Curr Gastroenterol Rep. 2019. https://doi.org/10.1007/s11894-019-0706-5. CrossRefPubMed

59.

Swain MG, Jones DEJ. Fatigue in chronic liver disease: new insights and therapeutic approaches. Liver Int. 2018. https://doi.org/10.1111/liv.13919.CrossRefPubMed

60.

Newton JL, Gibson GJ, Tomlinson M, Wilton K, Jones D. Fatigue in primary biliary cirrhosis is associated with excessive daytime somnolence. Hepatology. 2006;44(1):91–8. https://doi.org/10.1002/HEP.21230.CrossRefPubMed

61.

Ahmed MH, Byrne CD. Obstructive sleep apnea syndrome and fatty liver: association or causal link? World J Gastroenterol. 2010. https://doi.org/10.3748/wjg.v16.i34.4243.CrossRefPubMedPubMedCentral

62.

Bruyneel M, Sersté T. Sleep disturbances in patients with liver cirrhosis: prevalence, impact, and management challenges. Nat Sci Sleep. 2018;10:369. https://doi.org/10.2147/NSS.S186665.CrossRefPubMedPubMedCentral

63.

Jopson L, Dyson JK, Jones DEJ. Understanding and treating fatigue in primary biliary cirrhosis and primary sclerosing cholangitis. Clin Liver Dis. 2016;20(1):131–42. https://doi.org/10.1016/J.CLD.2015.08.007.CrossRefPubMed

64.

Bajaj JS, Ellwood M, Ainger T, et al. Mindfulness-based stress reduction therapy improves patient and caregiver-reported outcomes in cirrhosis. Clin Transl Gastroenterol. 2017;8(7):e108. https://doi.org/10.1038/CTG.2017.38.CrossRefPubMedPubMedCentral

65.

Piche T, Vanbiervliet G, Cherikh F, et al. Effect of ondansetron, a 5-HT3 receptor antagonist, on fatigue in chronic hepatitis C: a randomised, double blind, placebo controlled study. Gut. 2005;54(8):1169–73. https://doi.org/10.1136/GUT.2004.055251.CrossRefPubMedPubMedCentral

66.

Silveira MG, Gossard AA, Stahler AC, et al. A randomized, placebo-controlled clinical trial of efficacy and safety: modafinil in the treatment of fatigue in patients with primary biliary cirrhosis. Am J Ther. 2017;24(2):e167–76. https://doi.org/10.1097/MJT.0000000000000387.CrossRefPubMed

67.

Spahr L, Coeytaux A, Giostra E, Hadengue A, Annoni JM. Histamine H1 blocker hydroxyzine improves sleep in patients with cirrhosis and minimal hepatic encephalopathy: a randomized controlled pilot trial. Am J Gastroenterol. 2007;102(4):744–53. https://doi.org/10.1111/J.1572-0241.2006.01028.X.CrossRefPubMed

68.

Sharma MK, Kainth S, Kumar S, et al. Effects of zolpidem on sleep parameters in patients with cirrhosis and sleep disturbances: a randomized, placebo-controlled trial. Clin Mol Hepatol. 2019;25(2):199. https://doi.org/10.3350/CMH.2018.0084.CrossRefPubMedPubMedCentral

69.

Ge PS, Runyon BA. Treatment of patients with cirrhosis. N Engl J Med. 2016;375(8):767–77. https://doi.org/10.1056/NEJMRA1504367.CrossRefPubMed

Titel: Symptom Management in Patients with Cirrhosis: a Practical Guide
verfasst von: Alyson Kaplan
Russell Rosenblatt
Publikationsdatum: 17.03.2022
Verlag: Springer US
Erschienen in: Current Treatment Options in Gastroenterology / Ausgabe 2/2022
Print ISSN: 1092-8472
Elektronische ISSN: 1534-309X
DOI: https://doi.org/10.1007/s11938-022-00377-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Symptom Management in Patients with Cirrhosis: a Practical Guide

Abstract

Purpose of the review

Recent findings

Summary

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose of the review

Recent findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2022

Prevention of Duodenoscope-Associated Infections

Pre-transplant Cardiovascular Risk Assessment and Modification

POEM for Achalasia and Esophageal Motility Diseases: What Are the Knowledge Gaps?

Incidental Young-Onset Adenomas: Sporadic Findings or Harbingers of Increased Colon Cancer Risk?

Evidence for and Against Liver Transplantation for Acute-on-Chronic Liver Failure

The Impact of Social Workers in Cirrhosis Care: a Systematic Review

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin